Larimar Therapeutics, Inc. (LRMR) Guidance & Earnings Results
On 2026-03-19 Larimar Therapeutics, Inc. reaffirmed guidance: "BLA submission June 2026; U.S. launch first-half…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
LRMRLarimar Therapeutics, Inc.Follow LRMR — free
—
Price chart with a free account
- Market cap
- 244.1M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 19 Mar 26 | Reaffirmed | BLA submission June 2026; U.S. launch first-half 2027 · full year |
Larimar Therapeutics, Inc. — questions
- What guidance did Larimar Therapeutics, Inc. give?
- On 2026-03-19: "BLA submission June 2026; U.S. launch first-half 2027"
- When does Larimar Therapeutics, Inc. report earnings?
- Larimar Therapeutics, Inc.'s next earnings report is expected on 2026-11-05.
Every figure on this page comes from Larimar Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.